Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Stereotactic Body Radiotherapy for High-Risk Localized Carcinoma of the Prostate (SHARP) Consortium: Analysis of 344 Prospectively Treated Patients.
van Dams R, Jiang NY, Fuller DB, Loblaw A, Jiang T, Katz AJ, Collins SP, Aghdam N, Suy S, Stephans KL, Yuan Y, Nickols NG, Murthy V, Telkhade TP, Kupelian PA, Steinberg ML, Romero T, Kishan AU. van Dams R, et al. Among authors: jiang ny. Int J Radiat Oncol Biol Phys. 2021 Jul 1;110(3):731-737. doi: 10.1016/j.ijrobp.2021.01.016. Epub 2021 Jan 23. Int J Radiat Oncol Biol Phys. 2021. PMID: 33493615 Free PMC article. Clinical Trial.
Multi-Institutional Analysis of Prostate-Specific Antigen Kinetics After Stereotactic Body Radiation Therapy.
Jiang NY, Dang AT, Yuan Y, Chu FI, Shabsovich D, King CR, Collins SP, Aghdam N, Suy S, Mantz CA, Miszczyk L, Napieralska A, Namysl-Kaletka A, Bagshaw H, Prionas N, Buyyounouski MK, Jackson WC, Spratt DE, Nickols NG, Steinberg ML, Kupelian PA, Kishan AU. Jiang NY, et al. Int J Radiat Oncol Biol Phys. 2019 Nov 1;105(3):628-636. doi: 10.1016/j.ijrobp.2019.06.2539. Epub 2019 Jul 2. Int J Radiat Oncol Biol Phys. 2019. PMID: 31276777
Prostate-specific antigen kinetics and biochemical control following stereotactic body radiation therapy, high dose rate brachytherapy, and low dose rate brachytherapy: A multi-institutional analysis of 3502 patients.
Levin-Epstein R, Cook RR, Wong JK, Stock RG, Jeffrey Demanes D, Collins SP, Aghdam N, Suy S, Mantz C, Katz AJ, Nickols NG, Miszczyk L, Napieralska A, Namysl-Kaletka A, Prionas ND, Bagshaw H, Buyyounouski MK, Cao M, Mahal BA, Shabsovich D, Dang A, Yuan Y, Rettig MB, Chang AJ, Jackson WC, Spratt DE, Lehrer EJ, Zaorsky NG, Kupelian PA, Steinberg ML, Horwitz EM, Jiang NY, Kishan AU. Levin-Epstein R, et al. Among authors: jiang ny. Radiother Oncol. 2020 Oct;151:26-32. doi: 10.1016/j.radonc.2020.07.014. Epub 2020 Jul 11. Radiother Oncol. 2020. PMID: 32663537
Dose-response with stereotactic body radiotherapy for prostate cancer: A multi-institutional analysis of prostate-specific antigen kinetics and biochemical control.
Levin-Epstein RG, Jiang NY, Wang X, Upadhyaya SK, Collins SP, Suy S, Aghdam N, Mantz C, Katz AJ, Miszczyk L, Napieralska A, Namysl-Kaletka A, Prionas N, Bagshaw H, Buyyounouski MK, Cao M, Agazaryan N, Dang A, Yuan Y, Kupelian PA, Zaorsky NG, Spratt DE, Mohamad O, Feng FY, Mahal BA, Boutros PC, Kishan AU, Juarez J, Shabsovich D, Jiang T, Kahlon S, Patel A, Patel J, Nickols NG, Steinberg ML, Fuller DB, Kishan AU. Levin-Epstein RG, et al. Among authors: jiang ny. Radiother Oncol. 2021 Jan;154:207-213. doi: 10.1016/j.radonc.2020.09.053. Epub 2020 Oct 7. Radiother Oncol. 2021. PMID: 33035622 Free PMC article.
Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer.
Kishan AU, Dang A, Katz AJ, Mantz CA, Collins SP, Aghdam N, Chu FI, Kaplan ID, Appelbaum L, Fuller DB, Meier RM, Loblaw DA, Cheung P, Pham HT, Shaverdian N, Jiang N, Yuan Y, Bagshaw H, Prionas N, Buyyounouski MK, Spratt DE, Linson PW, Hong RL, Nickols NG, Steinberg ML, Kupelian PA, King CR. Kishan AU, et al. JAMA Netw Open. 2019 Feb 1;2(2):e188006. doi: 10.1001/jamanetworkopen.2018.8006. JAMA Netw Open. 2019. PMID: 30735235 Free PMC article.
Cervical gross tumor volume dose predicts local control using magnetic resonance imaging/diffusion-weighted imaging-guided high-dose-rate and positron emission tomography/computed tomography-guided intensity modulated radiation therapy.
Dyk P, Jiang N, Sun B, DeWees TA, Fowler KJ, Narra V, Garcia-Ramirez JL, Schwarz JK, Grigsby PW. Dyk P, et al. Int J Radiat Oncol Biol Phys. 2014 Nov 15;90(4):794-801. doi: 10.1016/j.ijrobp.2014.07.039. Epub 2014 Sep 20. Int J Radiat Oncol Biol Phys. 2014. PMID: 25245584
Study on Efficacy and Safety of Low-Dose Apatinib Combined with Camrelizumab and SOX Regimen as First-Line Treatment of Locally Advanced and Unresectable Gastric/Gastroesophageal Junction Cancer: A Protocol for an Open-Label, Dose Escalation and Extension Phase Ib Clinical Trial.
Wang KX, Cui TY, Yang XD, Wang GQ, Jiang QS, Sun H, Jiang NY, Yong XM, Shi CB, Ding YB, Chen XF, Fang YY. Wang KX, et al. Among authors: jiang ny. Onco Targets Ther. 2021 Sep 21;14:4859-4865. doi: 10.2147/OTT.S316288. eCollection 2021. Onco Targets Ther. 2021. PMID: 34584426 Free PMC article.
41 results